$21.63
5.87% yesterday
Nasdaq, Oct 15, 10:13 pm CET
ISIN
US03969K1088
Symbol
ARQT

Arcutis Biotherapeutics Inc Stock price

$21.63
+4.70 27.76% 1M
+8.44 63.99% 6M
+7.70 55.28% YTD
+12.28 131.34% 1Y
+2.23 11.49% 3Y
-2.33 9.72% 5Y
-0.17 0.78% 10Y
-0.17 0.78% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+1.20 5.87%
ISIN
US03969K1088
Symbol
ARQT
Industry

Key metrics

Basic
Market capitalization
$2.6b
Enterprise Value
$2.5b
Net debt
positive
Cash
$190.8m
Shares outstanding
119.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
9.8 | 7.7
EV/Sales
9.5 | 7.4
EV/FCF
negative
P/B
18.7
Financial Health
Equity Ratio
45.2%
Return on Equity
-88.9%
ROCE
-34.5%
ROIC
-
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$263.5m | $339.0m
EBITDA
$-80.7m | $-35.6m
EBIT
$-85.8m | $-55.1m
Net Income
$-93.3m | $-56.2m
Free Cash Flow
$-81.3m
Growth (TTM | estimate)
Revenue
99.5% | 72.5%
EBITDA
54.7% | 71.7%
EBIT
52.3% | 57.1%
Net Income
53.1% | 59.9%
Free Cash Flow
54.1%
Margin (TTM | estimate)
Gross
89.1%
EBITDA
-30.6% | -10.5%
EBIT
-32.6%
Net
-35.4% | -16.6%
Free Cash Flow
-30.9%
More
EPS
$-0.7
FCF per Share
$-0.7
Short interest
14.9%
Employees
342
Rev per Employee
$570.0k
Show more

Is Arcutis Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Arcutis Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Arcutis Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
263 263
100% 100%
100%
- Direct Costs 29 29
183% 183%
11%
235 235
93% 93%
89%
- Selling and Administrative Expenses 250 250
19% 19%
95%
- Research and Development Expense 71 71
23% 23%
27%
-81 -81
55% 55%
-31%
- Depreciation and Amortization 5.13 5.13
247% 247%
2%
EBIT (Operating Income) EBIT -86 -86
52% 52%
-33%
Net Profit -93 -93
53% 53%
-35%

In millions USD.

Don't miss a Thing! We will send you all news about Arcutis Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcutis Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
10 days ago
ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere on the body for any duration About 1.8 million children ages 2 to 5 with atopic dermatitis are topically treated in the U.S. Sixth FDA approval for ZORYVE in just over three years Commercial produc...
Neutral
GlobeNewsWire
13 days ago
WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,500 restricted stock units of Arcutis' common stock to 12 newly hired employees. These awards were approved by the Compensation Co...
Neutral
GlobeNewsWire
17 days ago
WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025 financial results on Tuesday, October 28, 2025, before the U.S. financial markets open.
More Arcutis Biotherapeutics Inc News

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.

Head office United States
CEO Todd Watanabe
Employees 342
Founded 2016
Website arcutis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today